International Journal of Hematology and Oncology 2019, Vol 29, Num 1 Page(s): 186-186
Correlation of BCRP Expression to NPM1 Mutations in Acute Myeloid Leukemia

Tayebeh SOHRABI1, Hossein AYATOLLAHI2, Mohsen ROKNI1, Samaneh HOUSHMAND1, Zahra ZAFARI1, Mohammad H. SADEGHIAN2, Mohammad R. KERAMATI2

1Mashhad University of Medical Sciences, Faculty of Medicine, Department of Hematology and Blood Bank, Mashhad, IRAN
2Mashhad University of Medical Sciences, Cancer Molecular Pathology Research Center, Mashhad, IRAN
3Tehran University of Medical Sciences, School of Public Health, Department of Immunology, Tehran, IRAN

Keywords: Acute myeloid leukemia, NPM1, BCRP, Real-Time PCR
Nucleophosmin1 (NPM1) mutation is a new prognostic factor for acute myeloid leukemia. Significant complete remission after chemotherapy has been observed in patients with this mutation compared to non-mutated patients. Overexpression of breast cancer resistance protein (BCRP) is directly associated with multiple drug resistance in leukemia. The aim of this study was to identify the effect of normal and mutated NPM1 on the expression of BCRP in AML patients. This cross-sectional study was conducted on 80 AML patients and 20 healthy individuals as the control group between 2012 and 2017. NPM1 mutations were observed with the PCR technique and the BCRP expression was measured by real-time PCR. Screening of the 80 AML patients revealed NPM1 mutation in 9 (11.2%) of them. The average expression of BCRP decreased significantly in the AML patient group in com-parison with the control group (p< 0.001). No statistically significant difference was observed between NPM1 mutation and BCRP expression in both groups with and without NPM1 mutations (p= 0.394). Unlike other studies, no case of NPM1 mutation was reported in the M3 subtype. However, in this study, this mutation was observed in the M3 subtype, and should be investigated for genetic and racial factors’ implication. There was no correlation between NPM1 mutation and BCRP expression. There are independently prognostic and treatment management factors in AML patients, which should be examined and considered in order to determine the treatment process and evaluation of drug resistance.